Prostate cancer study seeks to lower drug doses without losing effect
NCT ID NCT05276492
First seen Nov 01, 2025 · Last updated Apr 25, 2026 · Updated 24 times
Summary
This study aimed to find the lowest effective dose of the prostate cancer drug abiraterone for men starting treatment. Researchers planned to enroll 50 men and test different doses over 12 weeks, measuring hormone levels and PSA. The study was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Chicago Medicine Comprehensive Cancer Center
Chicago, Illinois, 60637, United States
Conditions
Explore the condition pages connected to this study.